Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Karl Brendel
Observed names:
BRENDEL, Karl,
Brendel, Karl,
K. Brendel
Institution:
Ipsen (France)
Observed institutions:
Inserm,
Ipsen (France),
Assistance Publique – Hôpitaux de Paris,
Servier (France),
Hôpital Bichat-Claude-Bernard,
Université Paris Diderot,
Institut de Recherches Internationales Servier (France)
show all 7
ORCID:
0009-0004-7551-0758
Observed ORCID:
0009-0004-7551-0758
OpenAlex ID:
A5006595074
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R
2008
·
Emmanuelle Comets
, Karl Brendel
, et al.
·
Computer Methods and Programs in Biomedicine
·
450
Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide
2006
·
Karl Brendel
, Emmanuelle Comets
, et al.
·
Pharmaceutical Research
·
307
Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?
2007
·
Karl Brendel
, C??line Dartois
, et al.
·
Clinical Pharmacokinetics
·
194
Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey
2007
·
C. Dartois
, K. Brendel
, et al.
·
British Journal of Clinical Pharmacology
·
101
PDF
Evaluation of different tests based on observations for external model evaluation of population analyses
2009
·
Karl Brendel
, Emmanuelle Comets
, et al.
·
Journal of Pharmacokinetics and Pharmacodynamics
·
86
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy
2005
·
Céline Verstuyft
, Fabienne Marcellin
, et al.
·
AIDS
·
43
Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics
2010
·
Emmanuelle Comets
, Karl Brendel
·
French digital mathematics library (Numdam)
·
34
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
2017
·
Jordi Rodon
, Sophie Postel-Vinay
, et al.
·
European Journal of Cancer
·
30
Optimal Sampling Times for a Drug and its Metabolite using SIMCYP® Simulations as Prior Information
2012
·
Cyrielle Dumont
, France Mentré
, et al.
·
Clinical Pharmacokinetics
·
30
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment
2015
·
Sophie Peigné
, François Bouzom
, et al.
·
Journal of Pharmacokinetics and Pharmacodynamics
·
18
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
2021
·
Karl Brendel
, Tanios Bekaii‐Saab
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
16
Population pharmacokinetic analysis of indinavir in HIV‐infected patient treated with a stable antiretroviral therapy
2005
·
Karl Brendel
, Mayeule Legrand
, et al.
·
Fundamental and Clinical Pharmacology
·
15
The Evolving Role of In Vitro–In Vivo Correlation in Model‐Informed Drug Development: A Multi‐Stakeholder Perspective
2025
·
Marylore Chenel
, Sylvain Fouliard
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
6
PDF
Using Fisher Information Matrix to predict uncertainty in covariate effects and power to detect their relevance in Non-Linear Mixed Effect Models in pharmacometrics
2025
·
Lucie Fayette
, Karl Brendel
, et al.
·
Journal of Pharmacokinetics and Pharmacodynamics
·
5
PDF
Development and performance of npde for the evaluation of time-to-event models
2018
·
M. Cerou
, M. Lavielle
, et al.
·
Pharmaceutical Research
·
5
Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
2019
·
T. Macarulla
, K. Brendel
, et al.
·
Annals of Oncology
·
2
125O First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
2015
·
S. Postel-Vinay
, A. Hollebecque
, et al.
·
Annals of Oncology
·
2
Why Should Prediction Discrepancies Be Renamed Standardized Visual Predictive Check?
2011
·
Emmanuelle Comets
, Karl Brendel
, et al.
·
The Journal of Clinical Pharmacology
·
2
PDF
Optimising covariate allocation at design stage using Fisher Information Matrix for Non-Linear Mixed Effects Models in pharmacometrics
2025
·
Lucie Fayette
, Karl Brendel
, et al.
·
medRxiv
·
1
PDF
1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
2020
·
S. Ponce
, K. Brendel
, et al.
·
Annals of Oncology
·
1
Model evaluation in nonlinear mixed effect models
2010
·
Emmanuelle Comets
, Karl Brendel
·
1
Fisher information matrix computation for joint longitudinal and survival models to support clinical study design and covariate effect assessment
2026
·
Lucie Fayette
, Karl Brendel
, et al.
·
medRxiv
PDF
Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis
2026
·
Qing Xi Ooi
, Karl Brendel
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
Abstract 1665: Preclinical characterization of IPN60300, a first-in-class ITGA2 antibody-drug conjugate for cancer therapy
2026
·
Aurélie Courtin
, Benjamin Beaufils
, et al.
·
Cancer Research
Optimising covariate allocation at design stage using fisher information matrix for non-linear mixed effects models in pharmacometrics
2026
·
Lucie Fayette
, Karl Brendel
, et al.
·
Computational Statistics & Data Analysis
Show more works
View as search
Works count:
41
Citation count:
1,349
H-index:
12
I10-index:
12
Year
Topic
Type
